SPRO
Spero Therapeutics Inc
1.20$
-5.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | |
| 2.4% | 67.2% | -120.4% | 232.7% | 0.0% | 629.0% | 231.6% | – | – | – | – | – | – | |
| 97.6% | 32.8% | 100.0% | -132.7% | 100.0% | -529.0% | -131.6% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | |
| 64.4% | 22.5% | 412.3% | 232.7% | 199.5% | 191.7% | 231.6% | 90.4% | 282.1% | 14.1% | 1,127.5% | – | 47.8% | |
| 22.4% | 8.0% | 140.7% | 54.3% | 38.6% | 41.6% | 116.2% | 49.8% | 136.9% | 10.8% | 1,894.2% | – | 46.2% | |
| 105.2% | -36.0% | 432.6% | 54.3% | 238.0% | -384.6% | 119.2% | 120.7% | 359.7% | 20.8% | 3,021.7% | – | 86.0% | |
| -7.6% | 68.7% | -332.6% | -186.9% | -138.0% | -144.4% | -250.8% | -20.7% | -259.7% | 79.2% | -2,921.7% | – | 14.0% | |
| 0.0% | 1.3% | – | – | – | – | – | – | – | – | – | – | – | |
| -3.9% | 70.2% | -301.4% | -175.2% | -129.5% | -136.9% | -236.1% | -14.4% | -242.2% | 80.1% | -2,791.9% | – | 17.8% | |
| 8.7% | 0.5% | -2.2% | – | -2.2% | 1.9% | – | – | – | 0.7% | – | – | – | |
| -12.6% | 69.6% | -301.4% | -175.2% | -127.3% | -138.8% | -236.1% | -14.4% | -242.2% | 79.5% | -2,791.9% | – | 17.2% | |
| 13.7% | 70.2% | -301.4% | -175.2% | -129.4% | -138.6% | -247.8% | -20.0% | -240.4% | 80.1% | -2,791.9% | – | 17.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.